ENSC Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: NDRA POAI ADTX NBTX ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: ACCESS Newswire

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

2 months ago - By: ACCESS Newswire

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

3 months ago - By: ACCESS Newswire

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

3 months ago - By: The Motley Fool

Ensysce Biosciences Narrows Loss in Q2

3 months ago - By: ACCESS Newswire

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

4 months ago - By: Benzinga - Mentions: PBM ALGN DYAI SNGX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

4 months ago - By: ACCESS Newswire

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

4 months ago - By: ACCESS Newswire

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

5 months ago - By: ACCESS Newswire

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

5 months ago - By: ACCESS Newswire

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

5 months ago - By: ACCESS Newswire

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

6 months ago - By: ACCESS Newswire

Ensysce Biosciences Reports First Quarter 2025 Financial Results

6 months ago - By: ACCESS Newswire

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

7 months ago - By: ACCESS Newswire

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

7 months ago - By: ACCESS Newswire

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

8 months ago - By: ACCESS Newswire

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

7 months ago - By: ACCESS Newswire

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

8 months ago - By: ACCESS Newswire

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

7 months ago - By: ACCESS Newswire

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

7 months ago - By: Stocktwits - Mentions: VXF GM

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

8 months ago - By: ACCESS Newswire

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

8 months ago - By: ACCESS Newswire

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

9 months ago - By: Today's Marketplace

ENSYSCE BIOSCIENCES INC (ENSC) Stock News

ENSC Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Monday's Pre-Market Session

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Ensysce Biosciences Narrows Loss in Q2

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids